In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. Launch Delays Under NICE Predicted By Rx Industry

Executive Summary

Pharmaceutical launches could be delayed by two or more years under the U.K.' s recently implemented National Institute for Clinical Excellence, Glaxo Wellcome Corporate Affairs Director and Association of the British Pharmaceutical Industry President Michael Bailey maintained at a London press conference April 7.

You may also be interested in...

U.K. Regulators To Consider FDA-Style Transparency

The U.K.' s Medicines Control Agency will consider the adoption of FDA-style transparency to communicate information about its activities more effectively, according to a five-year review of the agency conducted by the U.K. Department of Health.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts